UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
Quarterly Report Under Section 13 or 15(d) of
The Securities Exchange Act of 1934
For quarter ended: June 30, 2002 Commission File No. 0-11178
-------
UTAH MEDICAL PRODUCTS, INC.
---------------------------
(Exact name of Registrant as specified in its charter)
UTAH 87-0342734
------------------------------- ------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
7043 South 300 West
Midvale, Utah 84047
---------------------
Address of principal executive offices
Registrant's telephone number: (801) 566-1200
--------------
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports) and; (2) has been subject to such
filing requirements for the past 90 days. Yes X No
--- --
The number of shares outstanding of the registrant's common stock as of
August 13, 2002: 4,905,000
---------
UTAH MEDICAL PRODUCTS, INC.
---------------------------
INDEX TO FORM 10-Q
------------------
PART I - FINANCIAL INFORMATION PAGE
----
Item 1. Financial Statements
Consolidated Condensed Balance Sheets as of
June 30, 2002 and December 31, 2001 .............................. 1
Consolidated Condensed Statements of Income for the
three and six months ended June 30, 2002 and June 30, 2001 ....... 2
Consolidated Condensed Statements of Cash Flows for the
six months ended June 30, 2002 and June 30, 2001 ................. 3
Notes to Consolidated Condensed Financial Statements ............. 4
Item 2. Management's Discussion and Analysis of
Financial Condition and Results of Operations ................ 6
PART II - OTHER INFORMATION
Item 6. Exhibits and Reports on Form 8-K ............................... 10
SIGNATURES ................................................................ 10
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES
--------------------------------------------
CONSOLIDATED CONDENSED BALANCE SHEETS AS OF
-------------------------------------------
JUNE 30, 2002 AND DECEMBER 31, 2001
-----------------------------------
(in thousands)
(unaudited) (audited)
ASSETS JUNE 30, 2002 DECEMBER 31, 2001
Current assets:
Cash $ 823 $ 370
Accounts receivable - net 3,458 3,585
Inventories 3,351 3,248
Other current assets 740 670
-------- --------
Total current assets 8,372 7,873
Property and equipment - net 8,990 8,877
Goodwill 8,533 8,533
Goodwill - accumulated amortization (2,288) (2,288)
-------- --------
Goodwill - net 6,245 6,245
Other intangible assets 2,586 2,586
Other intangible assets - accumulated amortization (2,052) (2,009)
-------- --------
Other intangible assets - net 534 577
-------- --------
TOTAL $ 24,141 $ 23,572
======== ========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 514 $ 457
Accrued expenses 1,631 2,017
-------- --------
Total current liabilities 2,145 2,474
Notes payable 0 2,501
Deferred income taxes 200 390
-------- --------
Total liabilities 2,345 5,365
-------- --------
Stockholders' equity:
Preferred stock - $.01 par value; authorized - 5,000
shares; no shares issued or outstanding
Common stock - $.01 par value; authorized - 50,000
shares; issued - June 30, 2002, 5,021 shares
December 31, 2001, 5,029 shares 50 50
Cumulative foreign currency translation adjustment (1,341) (1,816)
Retained earnings 23,087 19,973
-------- --------
Total stockholders' equity 21,796 18,207
-------- --------
TOTAL $ 24,141 $ 23,572
======== ========
see notes to consolidated condensed financial statements
-1-
UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES
--------------------------------------------
CONSOLIDATED CONDENSED STATEMENTS OF INCOME FOR THE
---------------------------------------------------
THREE AND SIX MONTHS ENDED JUNE 30, 2002 AND JUNE 30, 2001
----------------------------------------------------------
(in thousands - unaudited)
THREE MONTHS ENDED SIX MONTHS ENDED
JUNE 30, JUNE 30,
----------------- -----------------
2002 2001 2002 2001
------- ------- ------- -------
NET SALES $ 6,800 $ 6,794 $13,505 $13,361
COST OF SALES 2,883 2,873 5,772 5,677
------- ------- ------- -------
Gross Margin 3,917 3,921 7,733 7,684
------- ------- ------- -------
EXPENSES:
Selling, general and administrative 1,247 1,476 2,483 2,915
Research & development 68 94 126 194
------- ------- ------- -------
Total 1,315 1,570 2,609 3,109
------- ------- ------- -------
Income from Operations 2,602 2,351 5,124 4,575
OTHER INCOME 126 28 238 4
------- ------- ------- -------
Income Before Income Tax Expense 2,728 2,379 5,362 4,579
INCOME TAX EXPENSE 943 898 1,865 1,707
------- ------- ------- -------
Net Income $ 1,785 $ 1,481 $ 3,497 $ 2,872
======= ======= ======= =======
BASIC EARNINGS PER SHARE $ 0.36 $ 0.30 $ 0.70 $ 0.57
======= ======= ======= =======
DILUTED EARNINGS PER SHARE $ 0.33 $ 0.29 $ 0.65 $ 0.56
======= ======= ======= =======
SHARES OUTSTANDING - BASIC 5,017 5,014 5,020 5,012
======= ======= ======= =======
SHARES OUTSTANDING - DILUTED 5,367 5,195 5,367 5,155
======= ======= ======= =======
see notes to consolidated condensed financial statements
-2-
UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES
--------------------------------------------
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
-----------------------------------------------
FOR THE SIX MONTHS ENDED JUNE 30, 2002 AND JUNE 30, 2001
--------------------------------------------------------
(in thousands - unaudited)
JUNE 30,
------------------
2002 2001
------- -------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income $ 3,497 $ 2,872
------- -------
Adjustments to reconcile net income to net
cash provided by operating activities:
Depreciation and amortization 624 997
Provision for losses on accounts receivable 7 45
Loss on disposal of assets 0 6
Deferred income taxes (235) (74)
Tax benefit attributable to exercise of stock options 155 23
Changes in operating assets and liabilities:
Accounts receivable - trade 251 82
Accrued interest and other receivables (65) (16)
Inventories (57) (170)
Prepaid expenses (22) (78)
Accounts payable 45 (142)
Accrued expenses (420) (110)
------- -------
Total adjustments 283 563
------- -------
Net cash provided by operating activities 3,780 3,435
------- -------
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures for:
Property and equipment (300) (312)
------- -------
Net cash used in investing activities (300) (312)
------- -------
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock 455 138
Common stock purchased and retired (995) (69)
Proceeds from note payable 0 0
Repayments of note payable (2,501) (3,400)
------- -------
Net cash used in financing activities (3,041) (3,331)
------- -------
Effect of exchange rate changes on cash 14 (9)
NET INCREASE (DECREASE) IN CASH 453 (217)
CASH AT BEGINNING OF PERIOD 370 414
------- -------
CASH AT END OF PERIOD $ 823 $ 197
======= =======
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the period for income taxes $ 1,824 $ 1,832
Cash paid during the period for interest $ 18 $ 267
see notes to consolidated condensed financial statements
-3-
UTAH MEDICAL PRODUCTS, INC.
---------------------------
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
----------------------------------------------------
(unaudited)
(1) The unaudited financial statements presented herein have been prepared in
accordance with the instructions to form 10-Q and do not include all of the
information and note disclosures required by accounting principles generally
accepted in the United States. These statements should be read in conjunction
with the financial statements and notes included in the Utah Medical Products,
Inc. ("UTMD" or "the Company") annual report on form 10-K for the year ended
December 31, 2001. Although the accompanying financial statements have not been
examined by independent accountants in accordance with auditing standards
generally accepted in the United States, in the opinion of management, such
financial statements include all adjustments (consisting only of normal
recurring adjustments) necessary to summarize fairly the Company's financial
position and results of operations.
(2) Inventories at June 30, 2002 and December 31, 2001 (in thousands) consisted
of the following:
June 30, December 31,
2002 2001
------ ------
Finished goods $1,077 $1,142
Work-in-process 970 835
Raw materials 1,304 1,271
------ ------
Total $3,351 $3,248
====== ======
(3) Comprehensive Income. The Company translates the currency of its Ireland
subsidiary which comprises the only element of comprehensive income. Total
comprehensive income for the three and six months ending June 30, 2002 was (in
thousands) $2,307 and $3,972, respectively.
(4) In July 2001, SFAS No. 141, "Business Combinations" and SFAS No. 142,
"Goodwill and Other Intangible Assets" were issued. SFAS 142 is required to be
applied for fiscal years beginning after December 15, 2001. SFAS 142 addresses
financial accounting and reporting for acquired goodwill and other intangible
assets. It requires, among other things, that companies no longer amortize
goodwill, but instead test goodwill for impairment within six months of adopting
the statement and at least annually thereafter. The Company completed the
required initial goodwill impairment test, based on December 31, 2001
valuations, and determined that the book value of its goodwill associated with
its 1997 and 1998 acquisitions is not impaired. Amortization of the Company's
other intangible assets totaled (in thousands) $22 and $43 for the three and six
months ending June 30, 2002. The estimated aggregate amortization expense for
the years ending 2002, 2003, 2004, 2005 and 2006 is (in thousands) $81, $76,
$51, $51 and $50, respectively.
(5) Forward-Looking Information
This report contains certain forward-looking statements and information
relating to the Company that are based on the beliefs of management as well as
assumptions made by, and information currently available to, management. When
used in this document, the words "anticipate," "believe," "should," "project,"
"estimate," "expect," "intend" and similar expressions, as they relate to the
Company or its management, are intended to identify forward-looking statements.
Such statements reflect the current view of the Company respecting future events
and are subject to certain risks, uncertainties, and assumptions, including the
risks and uncertainties noted throughout the document. Although the Company has
attempted to identify important factors that could cause the actual results to
differ materially, there may be other factors that cause the forward statement
not to come true as anticipated, believed, projected, expected, or intended.
Should one or more of these risks or uncertainties materialize, or should
underlying assumptions prove incorrect, actual results may differ materially
from those described herein as anticipated, believed, projected, estimated,
expected, or intended.
General risk factors that may impact the Company's revenues include the
market acceptance of competitive products, obsolescence caused by new
technologies, the possible introduction by competitors of new products that
claim to have many of the advantages of UTMD's products at lower prices, the
timing and market acceptance of UTMD's own new product introductions, UTMD's
ability to efficiently manufacture its products,
-4-
including the reliability of suppliers, success in gaining access to important
global distribution channels, marketing success of UTMD's distribution and sales
partners, budgetary constraints, the timing of regulatory approvals for newly
introduced products, third party reimbursement, and access to U.S. hospital
customers, as that access continues to be constrained by group purchasing
decisions.
Risk factors, in addition to the risks outlined in the previous paragraph
that may impact the Company's assets and liabilities, as well as cash flows,
include risks inherent to companies manufacturing products used in health care
including claims resulting from the improper use of devices and other product
liability claims, defense of the Company's intellectual property, productive use
of assets in generating revenues, management of working capital including
inventory levels required to meet delivery commitments at a minimum cost, and
timely collection of accounts receivable.
Additional risk factors that may affect non-operating income include the
continuing viability of the Company's technology license agreements, actual cash
and investment balances, asset dispositions, and acquisition activities that may
require external funding.
(6) Events subsequent to June 30, 2002
On July 3, 2002, UTMD entered into a new unsecured revolving
line-of-credit agreement with U.S. Bank National Association which replaces its
prior line-of-credit. Under the agreement, the Company may borrow up to
$15,000,000 at a floating interest rate tied to Prime Rate or LIBOR, at UTMD's
election. Financial covenants per the agreement require the Company to maintain
certain minimum Net Worth and maximum Interest Bearing Debt to EBITDA ratios. A
copy of the agreement is filed as an exhibit to this Form 10-Q.
-5-
Item 2. Management's Discussion and Analysis of Financial Condition and Results
of Operations
General
UTMD manufactures and markets a well-established range of specialty
medical devices. The general characteristics of UTMD's business have not
materially changed over the last several reporting periods. The Company's Form
10-K Annual Report for the year ended December 31, 2001 provides a detailed
description of products, technologies, markets, regulatory issues, business
initiatives, resources and business risks, among other details, and should be
read in conjunction with this report. Because of the relatively short span of
time, results for any given three or six month period in comparison with a
previous three or six month period may not be indicative of comparative results
for the year as a whole. Dollar amounts in the report are expressed in
thousands, except per-share amounts or where otherwise noted.
Analysis of Results of Operations
a) Overview
In 2Q 2002, UTMD met its primary financial performance objectives: 1)
Return on Shareholders' Equity (ROE) exceeded 25% and 2) Earnings Per Share
(EPS) increased 17% to $.333 on a diluted basis. UTMD concluded its eighteenth
consecutive quarter of higher EPS when compared to the same quarter in the prior
year. EPS for the last twelve months (LTM) were $1.23.
Profit margins (profits as a percentage of sales) at all income statement
levels continued exceptionally strong: 1) Gross Profit Margin (GPM) = 57.6%, 2)
Operating Profit Margin (OPM) = 38.3%, 3) Earnings Before Tax Margin (EBTM) =
40.1%, and 4) Net Profit Margin (NPM) = 26.3%.
Total consolidated sales increased by 1% in first half (1H) 2002, led by
a 2% increase in domestic direct business activity. With its continued strong
positive cash flow, UTMD eliminated its long term debt balance.
b) Revenues
Revenue from product sales is generally recognized by UTMD at the time
the product is shipped and invoiced and collectibility is reasonably assured.
The Company accrues provisions for the estimated costs that may be incurred for
product warranties and unforeseen uncollectible accounts.
UTMD believes that revenue should be recognized at the time of shipment
as title generally passes to the customer at the time of shipment. This policy
meets the criteria of SAB 101 in that there is persuasive evidence of an
existing contract or arrangement, delivery has occurred, the price is fixed and
determinable and the collectibility is reasonably assured.
Total sales in 2Q 2002 were essentially the same as in 2Q 2001.
International sales increased 4%, domestic direct sales remained the same, and
domestic OEM sales declined 11%. International sales, which benefitted from a
weaker US Dollar, were $1,438 in 2Q 2002 compared to $1,385 in 2Q 2001. Of these
international sales, 61% were made in Europe during 2Q 2002, compared to 55% in
2Q 2001. Shipments from UTMD's Ireland facility in U.S. Dollar terms were up
12%. Domestic OEM sales are subject to fluctuations because OEM customers
purchase products in quantities that represent more than one quarter's supply.
First half (1H) 2002 total sales increased 1%, comprised of domestic
direct sales up 2%, domestic OEM sales down 12% and international sales up 1%
from 1H 2001. International sales in 1H 2002 were $2,751 compared to $2,716 in
1H 2001. Of these international sales, 57% were made in Europe during 1H 2002,
compared to 55% in 1H 2001.
Revenues by product category:
1. Obstetrics. Worldwide 2Q 2002 obstetrics product sales decreased 1%
compared to 2Q 2001 and represented 43% of total sales. 2Q 2002 sales dollars
were $2,945 compared to $2,988 in 2Q 2001. Obstetrics sales in 1H 2002 were
$5,854 compared to $5,945 in 1H 2001. In 1H 2002, obstetrics product sales also
represented 43% of total sales. In 1H 2002, domestic (U.S.) obstetrics sales
declined $36, about 1%. In 1H 2002, sales of the market-leading IUP catheter,
Intran(R) Plus, increased 2%, while vacuum-assisted delivery systems (VADS)
sales declined 15%.
2. Gynecology/ Electrosurgery/ Urology. Worldwide 2Q 2002 Gyn/ES/Uro
product sales increased 3% compared to 2Q 2001 and represented 19% of total
revenues. 2Q 2002 sales dollars were $1,321 compared to $1,288 in 2Q 2001.
Gyn/ES/ Uro product sales in 1H 2002 were 2,677 compared to 2,504 in 1H 2001. In
1H
-6-
2002, Gyn/ES/Uro product sales represented 20% of total revenues. 1H 2002 ES
product sales increased 6%. 1H 2002 OEM urology sales decreased $46, or 33%.
3. Neonatal. Worldwide 2Q 2002 neonatal product sales decreased 4% compared
to 2Q 2001 and represented 13% of total sales. 2Q 2002 sales dollars were $911
compared to $946 in 2Q 2001. Neonatal product sales in 1H 2002 were $1,845
compared to $1,811 in 1H 2001. In 1H 2002, neonatal product sales represented
14% of total revenues.
4. Blood Pressure Monitoring and accessories (BPM). Worldwide 2Q 2002 BPM
product sales increased 3% compared to 2Q 2001 and represented 24% of total
revenues. 2Q 2002 sales dollars were $1,622 compared to $1,572 in 2Q 2001. BPM
product sales in 1H 2002 were $3,129 compared to $3,101 in 1H 2001. In 1H 2002,
BPM product sales represented 23% of total revenues. In 1H 2002, international
BPM sales increased 9%.
c) Gross Profit
UTMD's GPMs in 2Q 2002 and 1H 2002 were 57.6% and 57.3%, respectively,
compared to 57.7% and 57.5% for the same periods in 2001. GPMs remained
consistent because product mix did not change significantly, and improved
manufacturing efficiencies offset increased labor-related costs.
Because of UTMD's small size and period-to-period fluctuations in OEM
business activity, allocations of fixed manufacturing overheads cannot be
meaningfully allocated between direct and OEM sales. Therefore, UTMD does not
report GPM by sales channels.
UTMD targets an average GPM greater than or equal to 55%, which it
believes is necessary to successfully support the significant operating expenses
required in a highly complex and competitive marketplace. Management expects to
continue to achieve its average GPM target during the remainder of 2002.
Expected favorable influences include growth in sales volume without a similar
increase in manufacturing overhead expenses, a larger percentage of total sales
from higher margin products and a continued emphasis on reengineering products
to reduce costs. Expected unfavorable influences are continued competitive
pressure on pricing and higher labor-related costs, including especially health
plan benefits for employees.
d) Operating Profit
2Q 2002 operating profits increased 11% to $2,602 from $2,351 in 2Q 2001.
Operating profit dollars increased 12% in 1H 2002 compared to 1H 2001. Total
operating expenses, including sales and marketing (S&M) expenses, research and
development (R&D) expenses and general and administrative (G&A) expenses, were
19.3% of sales in both 2Q 2002 and 1H 2002 compared to 23.1% of sales in 2Q 2001
and 23.3% of sales in 1H 2001. 2Q and 1H 2002 OPMs were 38.3% and 37.9%
respectively, compared to 34.6% and 34.3% in 2Q and 1H 2001, respectively. A
reduction in the Company's accrual rate for litigation expenses associated with
the patent infringement lawsuit (which received a favorable verdict in January),
and the cessation of amortization of goodwill dictated by FASB SFAS No. 142,
significantly helped reduce operating (G&A) expenses.
S&M expenses in 2Q 2002 were $639 or 9.4% of sales compared to $727 or
10.7% of sales in 2Q 2001. First half 2002 S&M expenses were 9.2% of sales
compared to 10.6% in 1H 2001. Because UTMD sells internationally through third
party distributors, its S&M expenses are predominantly for U.S. business
activity. Looking forward, UTMD expects higher S&M expenses during the remainder
of 2002 due to increased sales activity and new marketing initiatives.
R&D expenses in 2Q 2002 were $68 or 1.0% of sales compared to $94 or 1.4%
of sales in 2Q 2001. R&D expenses in 1H 2002 were 0.9% of sales compared to 1.5%
of sales in 1H 2001. Management expects R&D expenses to increase during the
remainder of 2002.
G&A expenses in 2Q 2002 were $607 or 8.9% of sales compared to $750 or
11.0% of 2Q 2001 sales. G&A expenses in 1H 2002 were 9.2% of sales compared to
11.2% of 1H 2001. G&A expenses include the Company's costs of litigation,
patents, shareholder relations activities and amortization of goodwill (GWA)
associated with acquisitions. Because of the new FASB accounting rules regarding
intangible assets, GWA was zero in 1H 2002. UTMD anticipates G&A expenses during
the remainder of 2002 will continue to be about 2 percentage points lower, as a
percent of sales, than in second half (2H) 2001.
-7-
e) Non-operating income (expense)
Non-operating income in 2Q 2002 was $126 compared to $29 in 2Q 2001, and
$239 in 1H 2002 compared to $3 in 1H 2001. The substantial improvement was
primarily a result of much lower interest costs on the Company's line of credit.
Interest expense was $248 lower in 1H 2002 than in 1H 2001. As anticipated, the
Company eliminated its line of credit balance during 2Q 2002. The average line
of credit balance for 1H 2002 was about $1.0 million compared to $8.3 million in
1H 2001. Royalty income, which UTMD receives for licensing its technology to
other companies, was similar in all periods.
f) Earnings Before Income Taxes
2Q 2002 and 1H 2002 earnings before income taxes (EBT) increased 15% and
17% respectively compared to the same periods in 2001. 2Q 2002 EBTM was 40.1%
compared to 35.0% in 2Q 2001. 1H 2002 EBTM was 39.7% compared to 34.3% in 1H
2001. UTMD was able to increase EBT as a percentage of sales because of
reductions in operating expenses without affecting sales activity and lower
interest expenses. For the year 2001, UTMD achieved an excellent EBTM of 35%.
Management expects higher EBTM performance during the remainder of 2002 compared
to 2H 2001.
g) Net Income and EPS
UTMD's net income (after taxes) expressed as a percentage of sales (NPM)
was 26.3% and 25.9% for 2Q and 1H 2002, respectively, compared to 21.8% and
21.5% for 2Q and 1H 2001, respectively. Net income in dollars was up 21% and 22%
for 2Q 2002 and 1H 2002, respectively. The effective income tax rate in 2Q and
1H 2002 was 34.6% and 34.8%, respectively, compared to 37.8% and 37.3% in 2Q and
1H 2001. The reduction in UTMD's estimated income tax rate was due to two
primary factors: actual litigation costs which exceeded the Company's accrual
rate and exercises of employee options. For employee options exercised and sold
in less than one year, the gain realized by the employee is tax deductible to
the Company. UTMD expects the tax deduction benefits from these factors to
continue during the rest of 2002, resulting in a lower income tax rate for 2002
compared to 2001.
Diluted 2Q 2002 EPS increased 17% to $.33 compared to $.29 in 2Q 2001.
Diluted 1H 2002 EPS increased 17% to $.65 compared to $.56 in 1H 2001. The
Company's increase in stock price had a retarding effect on EPS growth as a
result of dilution from option exercises and calculation for unexercised options
with an exercise price below the current market value. 2Q 2002 weighted average
number of diluted common shares (the number used to calculate diluted EPS) were
5,367,000 compared to 5,195,000 shares in 2Q 2001. Actual outstanding common
shares as of the end of 2Q 2002 were 5,021,000.
h) Return on Shareholders' Equity (ROE)
Annualized ROE in 2Q and 1H 2002 was 34% and 35%, respectively, compared
to 42% in both 2Q and 1H 2001. The higher ROE in the prior year resulted because
of the much higher financial leverage (debt) in the prior year. UTMD's goal is
to consistently achieve ROE in excess of 25%. UTMD's ROE has averaged about 30%
over the last 14 years. Management expects to achieve 30% ROE for the calendar
year 2002.
Liquidity and Capital Resources
i) Cash flows
Net cash provided by operating activities, including adjustments for
depreciation and other non-cash operating expenses, along with changes in
working capital, totaled $3,781 in 1H 2002, compared to $3,435 in 1H 2001.
The Company expended $300 during 1H 2002 for investing activities,
comprised entirely of purchases of property and equipment. During 1H 2001, the
Company used $312 to purchase property and equipment.
UTMD received $455 from issuing 58,582 shares of stock upon the exercise
of employee stock options in 1H 2002, and repurchased 66,000 shares at a cost of
$995. Employee option exercises were at an average price of $7.76 per share. In
1H 2001, the Company received $138 from option exercises of 20,096 shares and
paid $69 to repurchase 7,000 shares.
During 1H 2002, UTMD made repayments of $2,501 on its note payable,
eliminating the balance on the note, and received $0 in proceeds from the note.
During 1Q 2001, UTMD made repayments of $3,400 and received $0 in proceeds from
the note.
Management believes that future income from operations and effective
management of working capital will provide the liquidity needed to finance
normal growth plans. UTMD expects to use cash during the rest of
-8-
2002 to keep facilities, equipment and tooling in good working order, for
selective infusions of technological, marketing or product manufacturing rights
to broaden the Company's product offerings, for continued share repurchases,
and, if available for a reasonable price, acquisitions that strategically fit
UTMD's business and are accretive to performance. The revolving credit line will
be used for liquidity when the timing of acquisitions or repurchases of stock
require substantial cash.
j) Assets and Liabilities
The following discussion focuses on Balance Sheet changes since March
31, 2002. For changes since December 31, 2001, please refer to the Balance
Sheets provided with this report. June 30, 2002 total assets were $714 more than
at March 31, 2002. Current assets increased due to accumulation of cash
following elimination of the line of credit balance. Net property and equipment
increased because assets in Ireland appreciated in dollar terms due to the
weakening of the U.S. Dollar. Net intangible assets were only $22 lower after
UTMD's required adoption of FASB Statement No. 142, under which goodwill and
indefinite lived intangible assets are no longer amortized but are reviewed
annually, or more frequently if impairment indicators arise, for impairment.
UTMD does not expect its goodwill intangible assets to become impaired in the
foreseeable future. Cash (and equivalent) balances were $823 at June 30, 2002,
compared to $110 on March 31, 2002. Cash balances will increase during the rest
of 2002 with normal operations. Cash would only decrease if used for an
acquisition or share repurchases. Average inventory turns in 2Q 2002 remained
excellent at 3.5 times compared to 3.6 times in 2Q 2001. Accounts receivable
balances decreased during 2Q 2002 with higher sales activity, which yielded a
reduction in average "days in receivables" from 49 days at the end of the prior
quarter to 46 days. At the end of 2Q 2001, days in receivables were 50. Working
capital increased $1,115 due to the increase in cash and a concomitant decrease
in current liabilities, in particular accrued liabilities for litigation
expenses. As of June 30, 2002, due to elimination of the bank loan balance,
UTMD's total debt ratio (total liabilities/ total assets) decreased to 10% from
17% on March 31, 2002 and from 23% on December 31, 2001. The debt had been
incurred in September 2000 to finance a Tender Offer repurchasing 1,119,000 UTMD
shares at $8.20/ share. Without additional share repurchases or acquisitions
that require new borrowing, UTMD anticipates a total debt ratio below 15% for
the remainder of the year.
Other Financial Measures
EBITDA is a measure of UTMD's ability to generate cash. EBITDA is EBT
plus depreciation and amortization expenses plus interest expenses resulting
from financing activities. 2Q 2002 EBITDA were $3,047, up from $2,982 in 2Q
2001. As a ratio of sales, EBITDA were 45% in 2Q 2002 compared to 44% in 2Q
2001. 1H 2002 EBITDA were $6,005, up from $5,843 in 1H 2001. LTM EBITDA were
$11,945.
Please note that EBITDA is not defined or described by Generally Accepted
Accounting Principles. As such, it is not prepared in accordance with GAAP, is
not a measure of liquidity, and is not a measure of operating results. However,
the components of EBITDA are prepared in accordance with GAAP, and UTMD believes
that EBITDA is an important measure of the Company's operating performance and
financial well-being.
k) Management's Outlook.
As outlined in its December 31, 2001 10-K report, UTMD's plan for 2002 is
to 1) realize improved results from 2001 initiatives to expand sales
activity;
2) continue outstanding operating performance, and set new Company records
for profitability as a percent of sales; 3) sustain the patent infringement
verdict and recover damages; and 4) actively look for new acquisitions to
build a platform for continued growth.
1H 2002 financial results are consistent with achieving the previously
stated plan.
Item 3. Quantitative and Qualitative Disclosures about Market Risk.
On January 1, 2002, UTMD converted the functional currency of its Irish
manufacturing operations, including related assets, to the Euro currency,
consistent with conversion of Ireland and many other Western European countries
to the new common Euro currency. The Company's Irish operations were previously
denominated in Irish Pounds. UTMD sells products under agreements denominated in
U.S. Dollars and the Euro. The exchange rate was 1.0055 Euros per U.S. Dollar as
of June 30, 2002. The weighted average conversion rate for 2Q 2002 for sales was
1.0793 Euros per U.S. Dollar. The Euro and other currencies are subject to
exchange rate fluctuations that are beyond the control or anticipation of UTMD.
The exchange rate for the Irish Pound was .9302 per U.S. Dollar as of June 30,
2001. The fixed exchange rate is .787 Euros per Irish Pound. UTMD manages its
foreign currency risk without separate hedging transactions by converting
currencies to U.S. Dollars as transactions occur.
-9-
PART II - OTHER INFORMATION
Item 6. Exhibits and Reports on Form 8-K
a) Exhibits:
SEC
Exhibit # Reference # Title of Document
- --------- ----------- -----------------
1 10 Loan Agreement, dated 3 July, 2002 between Utah
Medical Products, Inc. and U.S. Bank National
Association
2 10 Revolving Promissory Note, dated July 3, 2002,
by Utah Medical Products, Inc. to U.S. Bank
National Association
3 99 Certification of CEO pursuant to 18 U.S.C.ss.1350,
as Adopted Pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002
4 99 Certification of CFO pursuant to 18 U.S.C.ss.1350,
as Adopted Pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002
b) Reports on Form 8-K:
None
SIGNATURES
Pursuant to the requirements of the Securities Exchanges Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
UTAH MEDICAL PRODUCTS, INC.
---------------------------
REGISTRANT
Date: 8/14/02 By: /s/ Kevin L. Cornwell
------------------- --------------------------------------------
Kevin L. Cornwell
CEO
Date: 8/14/02 By: /s/ Greg A. LeClaire
------------------- --------------------------------------------
Greg A. LeClaire
CFO
-10-